Literature DB >> 22048791

Frontal assessment battery scores and non-motor symptoms in parkinsonian disorders.

Roberto Marconi1, Angelo Antonini, Paolo Barone, Carlo Colosimo, Tania P Avarello, Edo Bottacchi, Antonino Cannas, Maria G Ceravolo, Roberto Ceravolo, Giulio Cicarelli, Rosa M Gaglio, Luisa Giglia, Francesco Iemolo, Michela Manfredi, Giuseppe Meco, Alessandra Nicoletti, Massimo Pederzoli, Alfredo Petrone, Antonio Pisani, Francesco E Pontieri, Rocco Quatrale, Silvia Ramat, Rossana Scala, Giampiero Volpe, Salvatore Zappulla, Anna Rita Bentivoglio, Fabrizio Stocchi, Giorgio Trianni, Paolo Del Dotto, Danilo De Gaspari, Lucia Grasso, Francesca Morgante, Gabriella Santangelo, Giovanni Fabbrini, Letterio Morgante.   

Abstract

Using data from the PRIAMO study, we investigated non-motor symptoms (NMS) versus frontal lobe dysfunction in patients with idiopathic Parkinson disease (PD); 808 patients with PD and 118 with atypical parkinsonisms (AP) were consecutively enrolled at 55 Centers in Italy. Twelve categories of NMS were investigated. Cognitive impairment was defined as a Mini-Mental Status Evaluation score ≤ 23.8 and frontal lobe dysfunction as a Frontal Assessment Battery (FAB) score ≤ 3.48. Multivariable logistic regression was used to identify predictor of frontal lobe dysfunction in 524 PD patients, and a generalized linear model was used for each of the six FAB items. Not only the total FAB scores but also the single FAB items were lower in AP versus PD (p ≤ 0.005). Age (OR = 1.05), cognitive impairment (OR = 9.54), lack of cardiovascular symptoms (OR = 3.25), attention or memory problems (OR = 0.59) and treatment with L: -DOPA (OR = 5.58) were predictors of frontal lobe dysfunction. MMSE was negatively associated with all FAB items (β ≤ -0.16) and age with all FAB items but prehension behavior (β ≤ -0.01). Previous use of L: -DOPA was negatively associated with verbal fluency (β = -0.32) possibly acting as surrogate marker of disease duration. Cognitive impairment is a predictor of frontal lobe dysfunction. Among NMS, lack of attention or memory problems were negatively associated with frontal impairment. Further studies are nonetheless needed to better identify the predictors of frontal impairment in PD patients.

Entities:  

Mesh:

Year:  2011        PMID: 22048791     DOI: 10.1007/s10072-011-0807-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  28 in total

1.  Delayed response tasks in basal ganglia lesions in man: further evidence for a striato-frontal cooperation in behavioural adaptation.

Authors:  A Partiot; M Vérin; B Pillon; C Teixeira-Ferreira; Y Agid; B Dubois
Journal:  Neuropsychologia       Date:  1996-07       Impact factor: 3.139

2.  Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels.

Authors:  J Kulisevsky; A Avila; M Barbanoj; R Antonijoan; M L Berthier; A Gironell
Journal:  Brain       Date:  1996-12       Impact factor: 13.501

3.  The Frontal Assessment Battery (FAB): normative data from an Italian sample and performances of patients with Alzheimer's disease and frontotemporal dementia.

Authors:  Alessandro Iavarone; Bruno Ronga; Luigi Pellegrino; Elisa Loré; Sara Vitaliano; Filomena Galeone; Sergio Carlomagno
Journal:  Funct Neurol       Date:  2004 Jul-Sep

4.  The Frontal Assessment Battery (FAB): normative values in an Italian population sample.

Authors:  I Appollonio; M Leone; V Isella; F Piamarta; T Consoli; M L Villa; E Forapani; A Russo; P Nichelli
Journal:  Neurol Sci       Date:  2005-06       Impact factor: 3.307

5.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

6.  Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy.

Authors:  P Soliveri; D Monza; D Paridi; F Carella; S Genitrini; D Testa; F Girotti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

7.  Levodopa and executive performance in Parkinson's disease: a randomized study.

Authors:  Berta Pascual-Sedano; Jaime Kulisevsky; Manel Barbanoj; Carmen García-Sánchez; Antonia Campolongo; Alexandre Gironell; Javier Pagonabarraga; Ignasi Gich
Journal:  J Int Neuropsychol Soc       Date:  2008-09       Impact factor: 2.892

8.  A neuropsychological longitudinal study in Parkinson's patients with and without hallucinations.

Authors:  Gabriella Santangelo; Luigi Trojano; Carmine Vitale; Marta Ianniciello; Marianna Amboni; Dario Grossi; Paolo Barone
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

9.  High-speed memory scanning in Parkinson's disease: adverse effects of levodopa.

Authors:  W Poewe; W Berger; T Benke; L Schelosky
Journal:  Ann Neurol       Date:  1991-06       Impact factor: 10.422

10.  Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study.

Authors:  Gilbert Bensimon; Albert Ludolph; Yves Agid; Marie Vidailhet; Christine Payan; P Nigel Leigh
Journal:  Brain       Date:  2008-11-23       Impact factor: 13.501

View more
  5 in total

1.  Rasagiline for dysexecutive symptoms during wearing-off in Parkinson's disease: a pilot study.

Authors:  Domiziana Rinaldi; Francesca Assogna; Michela Sforza; Stefania Tagliente; Francesco E Pontieri
Journal:  Neurol Sci       Date:  2017-09-27       Impact factor: 3.307

2.  FAB-D: German version of the Frontal Assessment Battery.

Authors:  Thomas Benke; Elfriede Karner; Margarete Delazer
Journal:  J Neurol       Date:  2013-05-07       Impact factor: 4.849

3.  Performance on the Frontal Assessment Battery is sensitive to frontal lobe damage in stroke patients.

Authors:  Bruno Kopp; Nina Rösser; Sandra Tabeling; Hans Jörg Stürenburg; Bianca de Haan; Hans-Otto Karnath; Karl Wessel
Journal:  BMC Neurol       Date:  2013-11-16       Impact factor: 2.474

Review 4.  Assessing Executive Dysfunction in Neurodegenerative Disorders: A Critical Review of Brief Neuropsychological Tools.

Authors:  Helena S Moreira; Ana S Costa; São L Castro; César F Lima; Selene G Vicente
Journal:  Front Aging Neurosci       Date:  2017-11-09       Impact factor: 5.750

5.  Clinical Profile of Cognitive Decline in Patients with Parkinson's Disease, Progressive Supranuclear Palsy, and Multiple System Atrophy.

Authors:  Dipti Gupta; Anjani Kumar Sharma; Naveen Kumar
Journal:  J Neurosci Rural Pract       Date:  2017 Oct-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.